Reprint

Biliary Atresia: Aetiology, Diagnosis and Treatment

Edited by
May 2024
218 pages
  • ISBN978-3-7258-1217-2 (Hardback)
  • ISBN978-3-7258-1218-9 (PDF)

This book is a reprint of the Special Issue Biliary Atresia: Aetiology, Diagnosis and Treatment that was published in

Medicine & Pharmacology
Public Health & Healthcare
Summary

Despite extensive clinical and basic research, we know very little about the aetiology and pathomechanism of biliary atresia (BA). Today, it is a matter of common sense that early diagnosis (screening programs), sequential surgical treatment (the Kasai procedure and optional liver transplantation), and thorough follow-up in paediatric liver units improve survival rates among BA patients with native livers. However, BA still remains the most frequent indication of paediatric liver transplantation in patients with an unfavourable outcome after the Kasai procedure because the survival with native liver drops below 30% over the long term. Therefore, the following aspects should be considered alongside individual health issues: first, early organ replacement is a multifactorial burden for the growing organism, and second, every patient who survives with their native liver relieves the limited availability of donor organs and benefits national health expenditures with economic savings. From that point of view, international and interdisciplinary strategies are mandatory, in as much as BA is a rare disease. Over the past several years, national and international initiatives have been established in order to improve screening, centralization, diagnosis, as well as surgical and adjuvant treatment protocols. One such initiative is the recently launched European rare diseases network “rare-liver”.

Format
  • Hardback
License and Copyright
© 2024 by the authors; CC BY-NC-ND license
Keywords
biomarker; cholangiocyte; ductular reaction; liver fibrosis; pediatric liver disease; pregnancy; biliary atresia; chorine esterase; MELD score; liver transplantation; biliary atresia; Kasai operation; liver transplant; etiology; adjuvant therapy; biliary atresia; budesonide; adjuvant therapy; liver transplantation; biliary atresia; cholangitis; Kasai; hepatoportoenterostomy; biliary atresia; cytomegalovirus; survival native liver; antiviral treatment; biliary atresia; pediatric liver disease; newborn screening; public health; epidemiology; biliary atresia; liver nodules; hepatocellular carcinoma; regenerative nodules; focal nodular hyperplasia; biliary atresia; Kasai portoenterostomy; transplant waiting list; pediatric liver transplantation; referral practice; outcome; biliary atresia; kasai portoenterostomy; primary liver transplantation; outcomes; perinatal liver inflammation; innate immune system; monocytes; biliary atresia; cholangiopathy; biliary atresia; Kasai portoenterostomy; liver histology; transplant-free survival; biliary atresia; Kasai operation; adjuvant therapy; corticosteroids; cytomegalovirus; ursodeoxycholic acid; biliary atresia; cytomegalovirus; cytotoxic T cells; biliary atresia; perinatal liver injury; hematopoietic stem and progenitor cells; myeloid progenitor cells; liver; biliary atresia; transition; adolescence; adherence; readiness; professionals; parents; pediatric liver surgery; pediatric liver transplantation; hepatoblastoma; hepatocellular carcinoma; pediatric surgery workforce; subspecialization

Related Books

April 2022

New Therapies of Liver Diseases

Medicine & Pharmacology
January 2021

Diagnosis and Treatment of Small Bowel Disorders

Medicine & Pharmacology
September 2020

Newborn Screening for Cystic Fibrosis

Public Health & Healthcare
...